GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Product-specific reference

Lixisenatide (Adlyxin), adult single-ingredient SC injection

Read renal action and limits

Adlyxin

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Adlyxin - product and source limitations

GI adverse effects can produce dehydration and worsen kidney function. Verify the single-ingredient pen and the dated source.

Before applying: Verify the current prescribing information for this presentation.

Also check: Adlyxin - product and source limitations

Official source

Adlyxin - labeled renal guidance

Renal action and limits

Lixisenatide (Adlyxin), adult single-ingredient SC injection
Indexed GFR/eGFR, mL/min/1.73 m2

This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.

Action or finding
In mild or moderate impairment, no dose reduction is required; monitor renal function and adverse effects. Severe impairment (eGFR 15 to <30) has very limited experience and requires close monitoring. Use is not recommended in ESRD.
Limits and monitoring
GI adverse effects can produce dehydration and worsen kidney function. Verify the single-ingredient pen and the dated source.
Before use
Verify the current prescribing information for this presentation.

Prescribing information revised 9/2023 | Selected sections checked 2026-11-07. Independent clinical review pending.

Choose a product and source GlobalRPh RX passage All evidence
Product / population
Lixisenatide (Adlyxin), adult single-ingredient SC injection
Renal measure
Indexed GFR/eGFR, mL/min/1.73 m2
Source revision
Prescribing information revised 9/2023
Retrieved
2026-11-07 (not the revision date)
Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.

Renal guidance: 8.6

In mild or moderate impairment, no dose reduction is required; monitor renal function and adverse effects. Severe impairment (eGFR 15 to <30) has very limited experience and requires close monitoring. Use is not recommended in ESRD. GI adverse effects can produce dehydration and worsen kidney function. Verify the single-ingredient pen and the dated source.

Source revision: Prescribing information revised 9/2023 | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208471s007lbl.pdf

Scope: Selected renal passages reviewed; independent clinician adjudication pending. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Adlyxin - labeled renal guidance

Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.

Lixisenatide (Adlyxin), adult single-ingredient SC injection

Renal method: Indexed GFR/eGFR, mL/min/1.73 m2
Retrieved: 2026-11-07

GlobalRPh RX List

Adlyxin - selected RX renal passage

Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.

Lixisenatide (Adlyxin), adult single-ingredient SC injection

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Adlyxin - product and source limitations

GI adverse effects can produce dehydration and worsen kidney function. Verify the single-ingredient pen and the dated source.

How to use this: Verify the current prescribing information for this presentation.

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208471s007lbl.pdf

Product identity and scope

Lixisenatide (Adlyxin), adult single-ingredient SC injection

RDM73-adlyxin-identity-1 · Source section: Product identity and scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Adlyxin - labeled renal guidance

Open original reference

Open / share this exact local source

FDA / product prescribing information · Lixisenatide (Adlyxin), adult single-ingredient SC injection

Renal method: Indexed GFR/eGFR, mL/min/1.73 m2
Source date: Prescribing information revised 9/2023
Retrieved: 2026-11-07

Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 8.6

In mild or moderate impairment, no dose reduction is required; monitor renal function and adverse effects. Severe impairment (eGFR 15 to <30) has very limited experience and requires close monitoring. Use is not recommended in ESRD. GI adverse effects can produce dehydration and worsen kidney function. Verify the single-ingredient pen and the dated source.

RDM73-adlyxin-official-1 · Source locator: Renal guidance: 8.6

Source identity and provenance
Source family
product_label
Source
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208471s007lbl.pdf
Retrieved
2026-11-07
Renal-function method
Indexed GFR/eGFR, mL/min/1.73 m2
Source date/version
Prescribing information revised 9/2023
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
6b8d82ad958025ff19f22cbca6c5570c5f189f0f10b24548718bf14f90250a74
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Adlyxin - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Lixisenatide (Adlyxin), adult single-ingredient SC injection

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror emphasizes close surveillance for GI symptoms and changes in kidney function and the lack of therapeutic experience in ESRD.

RDM73-adlyxin-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/adlyxin-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
95f666c02c651e7dd12146bb51a6fb46bb84cf8c82a8516eb886d58f91824d76

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208471s007lbl.pdf
Source retrieval
2026-11-07. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
9ee4aa88046cae64ae4fa571861b63a6820cdc729d7939c1e0cad32a0c11ddd6
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report
Top